MétaCan
Menu
Back to cohort
Record W2172252732 · doi:10.1111/resp.12532

Year in review 2014: Interstitial lung disease, physiology, sleep and ventilation, acute respiratory distress syndrome, cystic fibrosis, bronchiectasis and rare lung disease

2015· review· en· W2172252732 on OpenAlexaff
Toby M. Maher, Amanda J. Piper, Yuanlin Song, Marcos I. Restrepo, Neil D. Eves

Bibliographic record

VenueRespirology · 2015
Typereview
Languageen
FieldMedicine
TopicInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Canadian institutionsUniversity of British Columbia, Okanagan CampusUniversity of British ColumbiaInterior Health
FundersNational Heart, Lung, and Blood InstituteNational Institutes of HealthGlaxoSmithKline
KeywordsMedicinePirfenidoneIdiopathic pulmonary fibrosisNintedanibInterstitial lung diseaseAdverse effectPopulationInternal medicineBronchiectasisCystic fibrosisIntensive care medicinePediatricsLung

Abstract

fetched live from OpenAlex

2014 was a seminal year for interstitial lung disease (ILD) with the announcement of three positive phase III clinical trials assessing treatments for the most devastating of the ILDs, idiopathic pulmonary fibrosis (IPF).1,2 Both pirfenidone and nintedanib were shown to be effective in slowing the progression of IPF with the consequence that both drugs have now been approved by the Federal Drugs Administration in the United States.While nintedanib is only now starting to be prescribed for patients, pirfenidone has been licensed in Europe since 2011 and Japan since 2008.3 With these new treatments, real-world experience of prescribing together with long-term safety studies will be important in defining the true costs and benefits of these first effective anti-fibrotic drugs.With this in mind, Valeyre et al. published an informative analysis of all patients treated to date in the CAPAC-ITY studies 4 and the open-label, rollover RECAP studies.5 This cohort included 789 subjects with a median pirfenidone exposure of 2.6 years (range 7 days to 7.7 years) and a cumulative exposure of 2059 patient-years.The adverse events noted mirrored those seen in shorter clinical trials with upper gastrointestinal disturbance and photosensitive rash predominating.Minor derangement of liver function tests was observed in 2.7% of the study population.Reassuringly, no hitherto unrecognized, rare adverse events were identified in this study population.The advent of effective therapies for IPF, a disease that had until recently been considered by many to be untreatable, has led to a considerable increase in clinical trial activity targeted at identifying novel approaches to inhibiting fibroproliferation.6 Chambers et al. reported a phase 1b trial of placentaderived mesenchymal stromal cells (MSC) in IPF.7 Eight subjects received escalating doses of MSC administered via a peripheral vein.In general, the treatment was well-tolerated and appeared to be safe.The study was not powered to determine efficacy, but at 6 months all subjects remained alive with stable disease.As noted by Glassberg and Toonkel in the accompanying editorial, the study raises at least as many questions as it answers but it has, at least, paved

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.008
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.056
Threshold uncertainty score0.189

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.008
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0050.002
Bibliometrics0.0090.008
Science and technology studies0.0010.001
Scholarly communication0.0060.004
Open science0.0020.002
Research integrity0.0040.004
Insufficient payload (model declined to judge)0.0560.015

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.016
GPT teacher head0.319
Teacher spread0.303 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueRespirologySame topicInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisFrench-language works237,207